Elicio Therapeutics, Inc.
ELTX
$4.80
$0.040.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.77% | 14.18% | 52.06% | 92.72% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.85% | 26.57% | 51.31% | 48.17% | -- |
| Operating Income | -25.85% | -26.57% | -51.31% | -48.17% | -- |
| Income Before Tax | -47.46% | -42.39% | -31.34% | -33.64% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.46% | -42.39% | -31.34% | -33.64% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.46% | -42.39% | -31.34% | -33.64% | -- |
| EBIT | -25.85% | -26.57% | -51.31% | -48.17% | -- |
| EBITDA | -26.30% | -27.18% | -52.44% | -49.23% | -- |
| EPS Basic | 85.85% | 91.45% | 94.19% | 93.35% | -- |
| Normalized Basic EPS | 85.94% | 91.46% | 94.21% | 93.12% | -- |
| EPS Diluted | 85.85% | 91.45% | 94.19% | 93.35% | -- |
| Normalized Diluted EPS | 85.94% | 91.46% | 94.21% | 93.12% | -- |
| Average Basic Shares Outstanding | 142.30% | 266.67% | 898.16% | 2,257.30% | -- |
| Average Diluted Shares Outstanding | 142.30% | 266.67% | 898.16% | 2,257.30% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |